A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial)

Sebastian L Johnston,1* Matyas Szigeti,2 Mary Cross,2 Christopher Brightling,3 Rekha Chaudhuri,4,5 Timothy Harrison,6 Adel Mansur,7,8 Laura Robison,2 Zahid Sattar,2 David Jackson,1 Patrick Mallia,1 Ernie Wong,1 Christopher Corrigan,9,10 Bernard Higgins,11 Philip Ind,1,12 Dave Singh,13 Neil Thomson,4 Deborah Ashby2 and Anoop Chauhan14 on behalf of the AZALEA trial team

1National Heart and Lung Institute, Imperial College London, London, UK
2Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK
3Institute for Lung Health, University of Leicester, Leicester, UK
4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
5Respiratory Medicine, NHS Greater Glasgow and Clyde, Glasgow, UK
6Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
7Respiratory Medicine, Heart of England NHS Foundation Trust, Birmingham, UK
8Severe and Brittle Asthma Unit, University of Birmingham, Birmingham, UK
9Department of Respiratory Medicine and Allergy, School of Medicine, King’s College London, London, UK
10Department of Asthma, Allergy and Respiratory Science, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
11Respiratory Medicine, Newcastle University, Newcastle, UK
12Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK
13Medicines Evaluation Unit (MEU), University of Manchester, Manchester, UK
14Respiratory Medicine, Portsmouth Hospitals NHS Trust, Portsmouth, UK

*Corresponding author
Declared competing interests of authors: Sebastian L Johnston has received institutional funding for a clinical trial and consultant compensation from Centocor, Sanofi Pasteur, GlaxoSmithKline and Synairgen; institutional funding for a research grant and consultant compensation from Chiesi, Boehringer Ingelheim and Novartis; and consultant compensation from Grünenthal. He is also a shareholder in Synairgen and has nine relevant licensed patents and one relevant patent pending. Christopher Brightling has received institutional grants and consultant compensation from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, Chiesi and Roche/Genentech. Dave Singh has received grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, and personal fees from Genentech and Skyepharma. Bernard Higgins has taken the role of local principal investigator for multicentre studies funded by Novartis and Roche. Christopher Corrigan has received a grant and personal fees for attendance at scientific conferences and payments for lectures from Allergy Therapeutics; a grant and personal fees from Novartis for research collaborations and consultancy not connected with the current research; a grant for attendance at scientific conferences from Stallergenes, Boehringer Ingelheim and Diagenics; and personal fees from AstraZeneca for speaking at conferences. Rekha Chaudhuri reports a grant and personal fees for attendance at scientific conferences and advisory board meetings: Novartis Pharmaceuticals, Astra-Zeneca, Teva and GlaxoSmithKline.

Published October 2016
DOI: 10.3310/eme03080

Plain English summary
The AZALEA trial
Efficacy and Mechanism Evaluation 2016; Vol. 3: No. 8
DOI: 10.3310/eme03080
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Acute asthma attacks are common and cause substantial suffering and, occasionally, death. Current treatments for asthma attacks are not as effective as they should be and new/better treatments are needed. Viral chest infections often cause asthma attacks and bacterial chest infections have also been associated with some attacks. However, current guidelines recommend that antibiotic therapy should not routinely be given, as a role for bacteria is uncertain. We previously reported that adults experiencing asthma attacks showed a significantly greater reduction in symptoms and faster recovery when given the antibiotic telithromycin compared with placebo (‘dummy’ treatment). However, safety concerns have limited the use of telithromycin. We therefore investigated whether or not azithromycin, which is similar to telithromycin, might be of benefit in asthma attacks through having an antibacterial, antiviral or anti-inflammatory effect.

In addition, we looked at (1) how frequently bacteria are detected in asthma attacks and (2) whether or not those people with a bacterial infection recovered better from an asthma attack. We recruited 199 patients into the study from 31 different centres. We could not demonstrate a statistically significant difference between the azithromycin group and the placebo group in patient diary scores or in any pulmonary function tests. There were no differences between groups in time to recovery. The numbers of bacterial infections were low and there was no suggestion of a treatment benefit in subjects with detectable bacteria.

For every patient randomised to treatment, approximately 10 other patients were not eligible to be included as they had already received antibiotic therapy. Conclusions were limited because not enough people participated in the trial.
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal
Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme
The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting ‘science driven’ studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report
The research reported in this issue of the journal was funded by the EME programme as project number 10/60/27. The contractual start date was in August 2011. The final report began editorial review in September 2015 and was accepted for publication in February 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Johnston et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Efficacy and Mechanism Evaluation Editor-in-Chief

Professor David Crossman  Bute Professor of Medicine and Dean and Head of Faculty of Medicine, University of St Andrews, and Honorary Consultant Cardiologist, NHS Fife Health Board, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk